Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (181-190 of 185) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 185 results.
ESMO Open|February 10, 2023
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatmentA A M van der Veldt, S F Oosting, R S N Fehrmann, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Pageof 19

Showing results (181-190 of 185) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 185 results.
ESMO Open|February 10, 2023
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatmentA A M van der Veldt, S F Oosting, R S N Fehrmann, et al.
Nature|October 2, 2019
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugsD L van der Velden, L R Hoes, H van der Wijngaart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS studyJ W T van der Wel, S M Ernst, M Jebbink, et al.
Lung Cancer (Amsterdam, Netherlands)|October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinibE Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
Pageof 19